{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:20:39Z","timestamp":1782458439264,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Polish National Science Center","award":["UMO-2016\/21\/B\/NZ6\/02279"],"award-info":[{"award-number":["UMO-2016\/21\/B\/NZ6\/02279"]}]},{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["DS460 and DS461"],"award-info":[{"award-number":["DS460 and DS461"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>COVID-19, a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), commonly presents as fever, cough, dyspnea, and myalgia or fatigue. Although the majority of patients with COVID-19 have mild symptoms, some are more prone to serious outcomes, including pneumonia, acute respiratory distress syndrome (ARDS), and even death. Hemophagocytic lymphohistiocytosis (HLH) is a severe, life-threatening inflammatory syndrome associated with intense cytokine release (also known as a \u201ccytokine storm\u201d). Similar to COVID-19, HLH is characterized by aggressive course leading to multi-organ failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main text<\/jats:title>\n                <jats:p>The purpose of this review article is to draw attention to the possibility of the complication of HLH in patients with the severe course of COVID-19. Indeed, some of the clinical characteristics observed in the more severe cases of COVID-19 are reminiscent of secondary HLH (which can be triggered by infections, malignancies, rheumatological diseases, or autoimmune\/immunodeficiency conditions). The pathogenesis of SARS-CoV-2 infection also suggests that HLH or a similar hyperinflammatory syndrome is the cause of the severe course of the infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The pathogenesis and clinical symptoms of severe COVID-19 indicate that an increased inflammatory response corresponding to HLH is occurring. Therefore, patients with severe COVID-19 should be screened for hyperinflammation using standard laboratory tests to identify those for whom immunosuppressive therapy may improve outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-020-01682-y","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:02:32Z","timestamp":1594771352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1644-5568","authenticated-orcid":false,"given":"Violetta","family":"Opoka-Winiarska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0451-4741","authenticated-orcid":false,"given":"Ewelina","family":"Grywalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-2651","authenticated-orcid":false,"given":"Jacek","family":"Roli\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"1682_CR1","unstructured":"Coronavirus disease (COVID-19) Pandemic [https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019]. Accessed 23 June 2020."},{"issue":"10223","key":"1682_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u201313.","journal-title":"Lancet"},{"key":"1682_CR3","doi-asserted-by":"publisher","unstructured":"Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, DSC H, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u20131720. https:\/\/doi.org\/10.1056\/NEJMoa2002032.","DOI":"10.1056\/NEJMoa2002032"},{"issue":"10223","key":"1682_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet"},{"issue":"9","key":"1682_CR5","doi-asserted-by":"publisher","first-page":"2000178","DOI":"10.2807\/1560-7917.ES.2020.25.9.2000178","volume":"25","author":"G Spiteri","year":"2020","unstructured":"Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, Bella A, Sognamiglio P, Sierra Moros MJ, Riutort AN, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25(9):2000178.","journal-title":"Euro Surveill"},{"issue":"11","key":"1682_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061\u20139.","journal-title":"JAMA"},{"key":"1682_CR7","doi-asserted-by":"publisher","unstructured":"Yang X, Yu Y, Xu J, Shu H, Xia JA, Liu H, Wu Y, Zhang L, Yu Z, Fang M et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475\u201381. https:\/\/doi.org\/10.1016\/S2213-2600(20)30079-5.","DOI":"10.1016\/S2213-2600(20)30079-5"},{"issue":"10229","key":"1682_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u201362.","journal-title":"Lancet"},{"issue":"1","key":"1682_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1080\/22221751.2020.1736644","volume":"9","author":"S-Y Fung","year":"2020","unstructured":"Fung S-Y, Yuen K-S, Ye Z-W, Chan C-P, Jin D-Y. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerging Microbes Infections. 2020;9(1):558\u201370.","journal-title":"Emerging Microbes Infections"},{"issue":"1","key":"1682_CR10","first-page":"11","volume":"7","author":"YR Guo","year":"2020","unstructured":"Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.","journal-title":"Mil Med Res"},{"key":"1682_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","volume":"63","author":"GE Janka","year":"2012","unstructured":"Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233\u201346.","journal-title":"Annu Rev Med"},{"key":"1682_CR12","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3389\/fimmu.2017.01902","volume":"8","author":"RA Marsh","year":"2018","unstructured":"Marsh RA. Epstein\u2013Barr virus and hemophagocytic lymphohistiocytosis. Front Immunol. 2018;8:1902.","journal-title":"Front Immunol"},{"issue":"9","key":"1682_CR13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/cid\/cir610","volume":"53","author":"LK Dropulic","year":"2011","unstructured":"Dropulic LK, Cohen JI. Severe viral infections and primary immunodeficiencies. Clin Infect Dis. 2011;53(9):897\u2013909.","journal-title":"Clin Infect Dis"},{"issue":"9927","key":"1682_CR14","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","volume":"383","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503\u201316.","journal-title":"Lancet"},{"key":"1682_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jcrc.2017.02.018","volume":"39","author":"X-C Han","year":"2017","unstructured":"Han X-C, Ye Q, Zhang W-Y, Tang Y-M, Xu X-J, Zhang T. Cytokine profiles as novel diagnostic markers of Epstein-Barr virus\u2013associated hemophagocytic lymphohistiocytosis in children. J Crit Care. 2017;39:72\u20137.","journal-title":"J Crit Care"},{"issue":"10","key":"1682_CR16","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.clml.2018.06.014","volume":"18","author":"E Apodaca","year":"2018","unstructured":"Apodaca E, Rodriguez-Rodriguez S, Tuna-Aguilar EJ, Demichelis-Gomez R. Prognostic factors and outcomes in adults with secondary hemophagocytic lymphohistiocytosis: a single-center experience. Clin Lymphoma Myeloma Leuk. 2018;18(10):e373\u201380.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"51","key":"1682_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002318","volume":"94","author":"T Barba","year":"2015","unstructured":"Barba T, Maucort-Boulch D, Iwaz J, Bohe J, Ninet J, Hot A, Lega JC, Guerin C, Argaud L, Broussolle C, et al. Hemophagocytic lymphohistiocytosis in intensive care unit: a 71-case strobe-compliant retrospective study. Medicine (Baltimore). 2015;94(51):e2318.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1682_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.23911","volume":"90","author":"ZK Otrock","year":"2015","unstructured":"Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220\u20134.","journal-title":"Am J Hematol"},{"issue":"1","key":"1682_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/16078454.2019.1660458","volume":"24","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Lu D, Ma S, Li L, Zhu J, Zhou, Zheng Y, Yang X, Zhu L, Zhu M, et al. Risk factors of early death in adult patients with secondary hemophagocytic lymphohistiocytosis: a single-institution study of 171 Chinese patients. Hematology. 2019;24(1):606\u201312.","journal-title":"Hematology"},{"issue":"5","key":"1682_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjh.12293","volume":"161","author":"GN Usmani","year":"2013","unstructured":"Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol. 2013;161(5):609\u201322.","journal-title":"Br J Haematol"},{"issue":"5","key":"1682_CR21","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.chest.2015.11.004","volume":"149","author":"A Seguin","year":"2016","unstructured":"Seguin A, Galicier L, Boutboul D, Lemiale V, Azoulay E. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest. 2016;149(5):1294\u2013301.","journal-title":"Chest"},{"issue":"2","key":"1682_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"J-I Henter","year":"2007","unstructured":"Henter J-I, Horne A, Aric\u00f3 M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124\u201331.","journal-title":"Pediatr Blood Cancer"},{"key":"1682_CR23","doi-asserted-by":"publisher","unstructured":"Hayden A, Lin M, Park S, Pudek M, Schneider M, Jordan MB, Mattman A, Chen LYC. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Advances. 2017;1(26):2529\u201334. https:\/\/doi.org\/10.1038\/s41375-020-0910-1.","DOI":"10.1038\/s41375-020-0910-1"},{"key":"1682_CR24","doi-asserted-by":"crossref","unstructured":"Li Q, Cao Y, Chen L, Wu D, Yu J, Wang H, He W, Chen L, Dong F, Chen W, et al. Hematological features of persons with COVID-19. Leukemia. 2020.","DOI":"10.1038\/s41375-020-0910-1"},{"issue":"9","key":"1682_CR25","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.ajem.2012.04.033","volume":"30","author":"JR Rodelo","year":"2012","unstructured":"Rodelo JR, De la Rosa G, Valencia ML, Ospina S, Arango CM, G\u00f3mez CI, Garc\u00eda A, Nu\u00f1ez E, Jaimes FA. D-dimer is a significant prognostic factor in patients with suspected infection and sepsis. Am J Emerg Med. 2012;30(9):1991\u20139.","journal-title":"Am J Emerg Med"},{"issue":"4","key":"1682_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844\u20137.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1682_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccc.2019.12.004","volume":"36","author":"S Valade","year":"2020","unstructured":"Valade S, Mariotte E, Azoulay E. Coagulation disorders in hemophagocytic lymphohistiocytosis\/macrophage activation syndrome. Crit Care Clin. 2020;36(2):415\u201326.","journal-title":"Crit Care Clin"},{"issue":"10229","key":"1682_CR28","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033\u20134.","journal-title":"Lancet"},{"issue":"3","key":"1682_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/path.2067","volume":"210","author":"L He","year":"2006","unstructured":"He L, Ding Y, Zhang Q, Che X, He Y, Shen H, Wang H, Li Z, Zhao L, Geng J, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006;210(3):288\u201397.","journal-title":"J Pathol"},{"issue":"5","key":"1682_CR30","doi-asserted-by":"publisher","first-page":"e1004077","DOI":"10.1371\/journal.ppat.1004077","volume":"10","author":"JL Nieto-Torres","year":"2014","unstructured":"Nieto-Torres JL, DeDiego ML, Verdi\u00e1-B\u00e1guena C, Jimenez-Guarde\u00f1o JM, Regla-Nava JA, Fernandez-Delgado R, Casta\u00f1o-Rodriguez C, Alcaraz A, Torres J, Aguilella VM, et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014;10(5):e1004077.","journal-title":"PLoS Pathog"},{"issue":"2","key":"1682_CR31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1128\/JVI.02576-13","volume":"88","author":"ML DeDiego","year":"2014","unstructured":"DeDiego ML, Nieto-Torres JL, Regla-Nava JA, Jimenez-Guarde\u00f1o JM, Fernandez-Delgado R, Fett C, Casta\u00f1o-Rodriguez C, Perlman S, Enjuanes L. Inhibition of NF-\u03baB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol. 2014;88(2):913\u201324.","journal-title":"J Virol"},{"key":"1682_CR32","doi-asserted-by":"publisher","unstructured":"Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;46(5):846\u20138. https:\/\/doi.org\/10.1007\/s00134-020-05991-x.","DOI":"10.1007\/s00134-020-05991-x"},{"key":"1682_CR33","unstructured":"Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by corona virus disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi. 2020;36(0):E005."},{"key":"1682_CR34","doi-asserted-by":"publisher","unstructured":"Ramachandran S, Zaidi F, Aggarwal A, Gera R. Recent advances in diagnostic and therapeutic guidelines for primary and secondary Hemophagocytic lymphohistiocytosis. Blood Cell Mol Dis. 2017;64:53\u201357. https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.023.","DOI":"10.1016\/j.bcmd.2016.10.023"},{"issue":"9","key":"1682_CR35","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613\u201320.","journal-title":"Arthritis Rheumatol"},{"issue":"23","key":"1682_CR36","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465\u201377.","journal-title":"Blood"},{"key":"1682_CR37","unstructured":"Hscore [http:\/\/saintantoine.aphp.fr\/score\/]. Accessed 23 June 2020."},{"issue":"8","key":"1682_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche J-D, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"6","key":"1682_CR39","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","volume":"2","author":"P Mehta","year":"2020","unstructured":"Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2(6):e358\u201367.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1682_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, Kochanek M, B\u00f6ll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J ImmunoTherapy Cancer. 2018;6(1):56.","journal-title":"J ImmunoTherapy Cancer"},{"issue":"1","key":"1682_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40779-020-0233-6","volume":"7","author":"Y-H Jin","year":"2020","unstructured":"Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, Fang C, Huang D, Huang L-Q, Huang Q, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Med Res. 2020;7(1):4.","journal-title":"Military Med Res"},{"issue":"9","key":"1682_CR42","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/ped.13064","volume":"58","author":"A Morimoto","year":"2016","unstructured":"Morimoto A, Nakazawa Y, Ishii E. Hemophagocytic lymphohistiocytosis: pathogenesis, diagnosis, and management. Pediatr Int. 2016;58(9):817\u201325.","journal-title":"Pediatr Int"},{"issue":"2","key":"1682_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/pbc.24039","volume":"59","author":"A Shiraishi","year":"2012","unstructured":"Shiraishi A, Ohga S, Doi T, Ishimura M, Takimoto T, Takada H, Miyamoto T, Abe Y, Hara T. Treatment choice of immunotherapy or further chemotherapy for Epstein\u2013Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2012;59(2):265\u201370.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1682_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1682_CR45","unstructured":"A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA). ClinicalTrials.gov Identifier: NCT04320615 [https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320615]. Accessed 23 June 2020."},{"key":"1682_CR46","unstructured":"A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry: ChiCTR2000029765 [http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49409]. Accessed 23 June 2020."},{"key":"1682_CR47","first-page":"1","volume":"44","author":"B Shakoory","year":"2015","unstructured":"Shakoory B, Carcillo J, Chatham W, Amdur R, Zhao H, Dinarello C, Cron R, Opal S. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome. Crit Care Med. 2015;44:1.","journal-title":"Crit Care Med"},{"key":"1682_CR48","unstructured":"Efficacy and safety of emapalumab and anakinra in reducing hyperinflammation and respiratory distress in patients with COVID-19 infection. ClinicalTrials.gov Identifier: NCT04324021 [https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04324021]. Accessed 23 June 2020."},{"issue":"10223","key":"1682_CR49","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30\u20131.","journal-title":"Lancet"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01682-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-020-01682-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01682-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T23:16:36Z","timestamp":1626304596000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01682-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1682"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01682-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}